Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?
- PMID: 35858498
- PMCID: PMC9254455
- DOI: 10.1016/j.msard.2022.104035
Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, mass vaccination was a beneficial strategy in many countries. Nevertheless, reports of serious complications such as postvaccination neuromyelitis optica spectrum disorder (NMOSD) raised concerns about the safety of vaccines. Anamnart and colleagues explained postvaccination NMOSD following different vaccines, including COVID-19. To emphasize the message of this article, in this letter, we present a unique case of postvaccination NMOSD with a fulminant and fatal course, which may show a plausible relationship between COVID-19 vaccination and triggering anti-aquaporin-4 antibody (AQP4-Ab).
Keywords: COVID-19 vaccine; NMOSD; Neuromyelitis optica spectrum disorder; Postvaccination.
Copyright © 2022. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Comment in
-
Fatal neuromyelitis optica after COVID-19 vaccination.Mult Scler Relat Disord. 2022 Dec;68:104089. doi: 10.1016/j.msard.2022.104089. Epub 2022 Aug 11. Mult Scler Relat Disord. 2022. PMID: 35987109 Free PMC article. No abstract available.
References
-
- Anamnart C, Tisavipat N, Owattanapanich W, Apiwattanakul M, Savangned P, Prayoonwiwat N, et al. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review. Mult. Scler. Relat. Disord. 2022;58 https://linkinghub.elsevier.com/retrieve/pii/S2211034821006805 Available from: - PubMed
-
- Awad A, Stüve O. Review: Cyclophosphamide in multiple sclerosis–Scientific rationale, history and novel treatment paradigms. Ther. Adv. Neurol. Disord. 2009;2(6):357–368. http://journals.sagepub.com/doi/10.1177/1756285609344375 Available from: - DOI - PMC - PubMed
-
- Krumbholz M, Hofstadt-van Oy U, Angstwurm K, Kleiter I, Jarius S, Paul F, et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J. Neurol. 2015;262(5):1379–1384. http://link.springer.com/10.1007/s00415-015-7766-8 Available from: - DOI - PMC - PubMed
-
- Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. https://www.neurology.org/lookup/doi/10.1212/WNL.0000000000001729 Available from: - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
